Controlled Human Infection Model Challenge/Rechallenge: Shigella Flexneri 2a and S. Sonnei Cross-protective Antigens Discovery in Healthy Adults in the United States
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- Percentage of Participants With Shigellosis Following Shigella Challenge
研究概览
简要总结
The goal of this study is to better understand Shigella immunity. The study will compare the shigellosis rate in participants previously challenged with a different Shigella serotype to the attack rate in participants not previously exposed to Shigella (naive participants).
详细描述
This is a single-center controlled human infection model (CHIM) study designed to assess the cross-protective efficacy and markers of protection after challenge and heterologous rechallenge with Shigella strains of different serotypes in naïve healthy adult volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adults, male or female, aged 18 to 50 years (all inclusive) at the time of enrollment.
- •General good health, without clinically significant medical history, physical examination findings, or clinical laboratory abnormalities per judgment of Principal Investigator (PI).
- •Willingness to participate in the study after all aspects of the protocol have been explained and written informed consent obtained.
- •Completion of a training session and demonstrated comprehension of the protocol procedures and knowledge of Shigella-associated illness by passing a written examination (70% passing score).
- •Availability for the study duration, including all planned follow-up visits.
- •Female participants must have a negative pregnancy test at screening and prior to each challenge.
- •Female participants must agree to avoid pregnancy for 29 days following the last challenge dose by use of an efficacious hormonal or barrier method of birth control during the study. Abstinence is acceptable. Female participants unable to bear children must have this documented (e.g., tubal ligation or hysterectomy).
- •Willingness to refrain from participation in a study of another investigational agent for 90 days following the last challenge dose.
排除标准
- •Presence of a significant medical or psychiatric condition that in the opinion of the investigator precludes participation in the study. Some medical conditions that are adequately treated and stable would not preclude entry into the study.
- •Clinically significant abnormalities in screening on physical exam or screening laboratory results as determined by PI or PI in consultation with the research monitor and Sponsor.
- •Recent receipt of another investigational product (within 30 days before enrollment).
- •Positive enzyme-linked immunosorbent assay (ELISA) and confirmatory tests for human immunodeficiency virus (HIV).
- •Positive hepatitis C (HCV) ELISA and confirmatory test (e.g., HCV ribonucleic acid (RNA)).
- •Positive hepatitis B virus surface antigen (HBsAg) by ELISA.
- •Use of any medication that affects immune function (e.g., corticosteroids and others) within 30 days preceding the first challenge or planned use during the active study period (topical and ophthalmologic steroids are allowable).
- •Evidence of impaired immune function or immune compromise (known immunodeficiency syndrome; either congenital, acquired, or iatrogenic; active autoimmune disease; repeated serious infections without known cause).
- •Immunoglobulin A (IgA) deficiency (serum IgA < 7 mg/dL or below the limit of detection of the assay).
- •Positive blood test for human leukocyte antigen (HLA)-B
- •Personal or family history of an inflammatory arthritis.
- •Currently pregnant or nursing.
- •Have household contacts who are < 2 years old or > 80 years old or infirm or immunocompromised.
- •Employment as a health care worker with direct patient care, in a daycare center (for children or the elderly), or direct food handler; includes individuals who work directly with food in commercial establishments.
- •Evidence of current alcohol or drug dependence, or history of dependence in the last 6 months.
- •Recent vaccination (including licensed vaccines) or receipt of an investigational product (within 30 days before challenge through 90 days following the last challenge dose). Annual influenza vaccine, an emergency authorized or licensed COVID-19 vaccine, or a TdaP or Travelers' diarrhea (TD) booster may be administered beyond 30 days after each challenge.
- •Treatment with immunoglobulins or blood products within 3 months of challenge.
- •Current or prior history of inflammatory bowel disease or irritable bowel syndrome or abnormal stool pattern (> 3/day or < 3/ week, or loose or liquid stools).
- •Chronic use of anti-diarrheal, anti-constipation, or antacid therapy; or use of these medications in the 7 days prior to challenge.
- •Use of proton pump inhibitors or H2 blockers (H2-receptor antagonists) within 48 hours prior to challenge.
- •Use of antibiotics within 7 days prior to challenge.
- •Known allergy to any 2 of the following antibiotics: ciprofloxacin, trimethoprim-sulfamethoxazole, or penicillin.
- •Symptoms of travelers' diarrhea associated with travel to countries where Shigella or other enteric infections are endemic (most of the developing world) within 3 years prior to challenge OR planned travel to endemic countries during the active study period.
- •History of shigellosis, Shigella vaccination or challenge, or a laboratory worker with known exposure to Shigella within the last 5 years.
- •Serum immunoglobulin G (IgG) titer > 2500 to either Shigella flexneri 2a or Shigella sonnei lipopolysaccharide.
- •Any other criteria which, in the investigator's opinion, would compromise the ability of the volunteer to participate in the study, the safety of the study, or the results of the study.
研究组 & 干预措施
Group 2B: S. Sonnei 53G (Naive)
At least 3 months after the challenge in Group 2A, newly recruited naïve participants were challenged with 1500 CFU of S. sonnei 53G.
干预措施: Shigella sonnei 53G (Biological)
Group 1A: S. sonnei 53G
Naïve participants were challenged with 1500 colony forming units (CFU) of S. sonnei strain 53G.
干预措施: Shigella sonnei 53G (Biological)
Group 1B: S. flexneri 2a 2457T (Naive)
At least 3 months after the challenge in Group 1A, newly recruited naïve participants were challenged with 1500 CFU of S. flexneri 2a strain 2457T.
干预措施: Shigella flexneri 2a 2457T (Biological)
Group 1B: S. Flexneri 2a (Veteran)
At least 3 months after challenge with S. sonnei 53G in Group 1A, participants received a 2nd challenge with 1500 CFU of S. flexneri 2a strain 2457T.
干预措施: Shigella flexneri 2a 2457T (Biological)
Group 2A: S. Flexneri 2a
Naïve participants were challenged with 1500 CFU of S. flexneri 2a strain 2457T.
干预措施: Shigella flexneri 2a 2457T (Biological)
Group 2B: S. Sonnei 53G (Veteran)
At least 3 months after challenge with S. flexneri 2a in Group 2A, participants received a 2nd challenge with 1500 CFU of S. sonnei 53G.
干预措施: Shigella sonnei 53G (Biological)
结局指标
主要结局
Percentage of Participants With Shigellosis Following Shigella Challenge
时间窗: 8 days after challenge administration (Days 1-8 and Days 90-97 for challenge 2)
Shigellosis was defined as: * Severe diarrhea: ≥ 6 loose (grade 3-5) stools within 24 hours or \>800 - 999 g loose stools within any 24-hour window, or * Moderate diarrhea (4 - 5 loose stools within 24 hours or 401-800 g loose stools within any 24-hour window) with fever (oral temperature of ≥ 101.2°F / 38°C) OR with ≥ 1 moderate constitutional or enteric symptom OR ≥ 2 episodes of vomiting in a 24-hour period, or * Dysentery: ≥ 2 loose stools with gross blood (hemoccult positive) in 24 hours AND fever OR ≥ 1 moderate constitutional/enteric symptom OR ≥ 2 episodes of vomiting in 24 hours. Constitutional/Enteric symptoms include nausea, abdominal cramps/pain, myalgia, arthralgia, or malaise. Stools were graded on the following scale: * Grade 1, firm formed; * Grade 2, soft formed; * Grade 3, viscous opaque liquid or semi-liquid; * Grade 4, watery opaque liquid; * Grade 5, clear watery or mucoid liquid. Outcome data were evaluated by an independent, blinded adjudication board.
次要结局
- Maximum Volume of Loose Stools in Any 24-hour Period(8 days after challenge administration (Days 1-8 and Days 90-97 for challenge 2))
- Percentage of Participants With Severe Diarrhea(8 days after challenge administration (Days 1-8 and Days 90-97 for challenge 2))
- Percentage of Participants With Diarrhea of Any Severity(8 days after challenge administration (Days 1-8 and Days 90-97 for challenge 2))
- Total Weight of Grade 3-5 Stools Per Participant After Challenge(8 days after challenge administration (Days 1-8 and Days 90-97 for challenge 2))
- Percentage of Participants With Nausea, Vomiting, Anorexia, Abdominal Pain/Cramps Rated as Moderate to Severe(8 days after challenge administration (Days 1-8 and Days 90-97 for challenge 2))
- Percentage of Participants With Dysentery(8 days after challenge administration (Days 1-8 and Days 90-97 for challenge 2))
- Time to Onset of Diarrhea(From challenge administration to the end of the 8-day inpatient period (Days 1-8 and Days 90-97 for challenge 2))
- Number of Participants With More Severe Diarrhea(8 days after challenge administration (Days 1-8 and Days 90-97 for challenge 2))
- Number of Participants With Fever After Challenge(8 days after challenge administration (Days 1-8 and Days 90-97 for challenge 2))
- Shigella Clinical Severity Score(8 days after challenge administration (Days 1-8 and Days 90-97 for challenge 2))
- Number of Colony Forming Units (CFUs) of the Challenge Strain Per Gram of Stool(8 days after challenge administration (Days 1-8 and Days 90-97 for challenge 2))